Ondine Biomedical (LON:OBI) Trading Down 1.7% – Here’s Why

Ondine Biomedical Inc. (LON:OBI) shares traded down 1.7% during mid-day trading on Wednesday . The stock traded as low as C$14.50 and last traded at C$14.50. Approximately 39,166 shares traded hands during mid-day trading, a decline of 91% from the average session volume of 448,011 shares. The stock had previously closed at C$14.75.

Ondine Biomedical Stock Down 1.7%

The company has a current ratio of 1.23, a quick ratio of 8.26 and a debt-to-equity ratio of 11.85. The stock has a market capitalization of C$7.53 billion, a P/E ratio of -2.07 and a beta of 0.32. The stock’s 50 day simple moving average is C$14.33 and its 200 day simple moving average is C$11.39.

Ondine Biomedical Company Profile

Ondine Biomedical is a life sciences company leading the charge in breakthrough photodisinfection-based therapies to prevent and treat serious infections, including those caused by existing, emerging, and antimicrobial-resistant pathogens.

Our vision is a world free from infections. We have created a patented, platform technology (photodisinfection) to provide simple solutions to complex infections across different therapeutic areas in healthcare and industry settings. We are focused on solutions that address significant needs, are easy to deploy, are environmentally safe, provide substantial public health benefits, and cost a fraction of the infections they target.

Our photodisinfection technology has been used successfully for many years in more than 100,000 patient treatments in hospitals, clinics, and industrial settings across Canada.